Index

a  
Aberrant crypt foci (ACF)  343  
ACE inhibitors  184, 246, 249, 252  
Acetaminophen (Paracetamol)  
  – Alzheimer’s disease  361f.  
  – analgesic action  324ff.  
  – analgesic nephropathy  180, 182  
  – asthma  197ff., 217ff.  
  – hepatotoxicity  188  
  – osteoarthritis  334f.  
  – renal failure  181f.  
Acetylsalicylic acid (ASA), see Aspirin  
Acute coronary syndrome, see Coronary vascular disease  
Adenomatous Polyposis Coli (APC)  118f., 343f., 346, 349, 354  
Allodynia  114  
Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT)  363  
Alzheimer’s disease  18, 359ff.  
  – actual situation  363  
  – clinical trials  361ff.  
  – etiology  359  
  – mode of aspirin action  360  
  – pathophysiology  359  
American Health Professionals’ study  233f.  
Angioedema  205  
Anticoagulants  
  – cerebrovascular disease  269ff.  
  – coronary vascular disease  247ff.  
  – peripheral arterial disease  282  
  – venous thrombosis  287f.  
Antiplatelet drugs  91f., 280, 289, 294  
Antiplatelet/anti thrombotic Trialists’ Collaboration  229  
Antipretic analgesics  322ff., 329, 340  
Antithrombotics in the Prevention of Reoclusion in Coronary Thrombolysis (APRICOT)  248  
Antitumorigenic effects, see Malignancies  
Apoptosis  69, 71, 118, 120ff., 354  
Aprotinin  146f.  
  – Arthritis and rheumatism  332ff.  
  – actual situation  336  
  – clinical trials  334f.  
  – mode of aspirin action  332ff.  
  – osteoarthritis  333ff.  
  – rheumatoid arthritis  332ff.  
Aspirin, see also Salicylate  
  – absorption  34ff., 40  
  – actions on organs and tissues  86ff.  
  – alcohol  146, 168  
  – analgesic/antipyretic actions  14, 86, 105, 111, 113f., 323 ff.  
  – antiinflammatory actions  106ff., 232  
  – antiplatelet actions  15, 86, 88, 90, 262  
  – antitumor effects  120ff.  
  – antiulcer drugs  170  
  – bioavailability  38f.  
  – biotransformations  46ff.  
  – bleeding risk  15, 142ff., 152, 159f., 244f.  
  – chemical properties  25ff.  
  – clinical applications  225ff.  
  – coagulation  98  
  – COX-independent actions  66ff., 122 ff.  
  – COX-inhibition  13f., 54ff., 120ff., 163f.  
  – desensitization  201  
  – determination  30ff.  
  – dosing  41, 88, 92, 226ff., 251, 262f., 352f.  
  – Ductus arteriosus  151f.  
  – energy metabolism  79ff.  
  – esterases  46ff.  
  – excretion  49ff.  
  – fertility  150  
  – fibrinolysis  98f., 242f.  
  – formulations  27ff., 40, 326  
  – hemostasis  89ff.  
  – hepatotoxicity  187f.  

Acetylsalicylic Acid. Karsten Schrör  
Copyright © 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim  
ISBN: 978-3-527-32109-4
Index

– history 5ff., 19ff.
– hypersensitivity, see also Aspirin-induced asthma 197ff.
– inhibition of platelet function 90ff.
– inhibition of prostaglandin formation 12, 53ff.
– inhibition of kinases 67ff.
– interactions with NSAIDs 60f. 170, 249f. 308f.
– miscarriage 151
– modes of action 53ff.
– pharmacokinetics 33ff., 46ff.
– pharmacological properties 225
– pseudoallergic actions 197ff.
– renal failure 181ff.
– “resistance” 303ff.
– sphingosine-1-phosphate 58
– thrombin generation 143f.
– toxicity 131ff.
– transcription factors 69ff., 123f.
Aspirin Esomeprazole Chemoprevention Trial (ASPECT) 312f.
Aspirin-induced asthma 197ff., 217f.
– clinical studies 201f.
– clinical symptoms 198f.
– leukotrienes 200f.
– mode of aspirin action 199f.
– pathophysiology 197ff.

“Aspirin-like drugs” 18, 60
Aspirin-Myocardial Infarction Study (AMIS) 17
Aspirin-triggered lipoxin (ATL) 59, 108f., 163f.
Atherosclerosis Risk in Communities Study (ARIC) 227
Audiovestibular system, see Ototoxicity

B
Baltimore Longitudinal Study of Ageing 361
Barbados Low-dose Aspirin Study in Pregnancy (BLASP) 294, 297
Bioavailability 38ff.
Biotransformations 46ff.
Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA) 270
Bleeding disorders 142ff.
– bleeding time 142ff.
– bleeding risk in surgical interventions 144ff.
– GI tract 159ff., 169f.
– hemorrhagic stroke 264
– pregnancy and labor 152
– role of platelets 143
British medical doctors’ study (BMDS) 232f., 264

C
Cancer, see Malignancies
Cancer prevention study II (CPS-II) 227, 347f.
Cardiovascular diseases, see also Coronary vascular diseases
– ACE-inhibitors 249
– statins 249
Celecoxib Long-term Arthritis Safety Study (CLASS) 171
Ceramide 121, 123
Cerebrovascular diseases 260ff.
– actual situation 270f.
– anticoagulants 269f.
– clopidogrel 269
– dipyridamole 267f.
– etiology 260
– hemorrhagic stroke 264f.
– mode of aspirin action 261ff.
– primary prevention 263ff.
– secondary prevention 265ff.
Chinese Acute Stroke Trial (CAST) 266f.
Cilostazol 283
Clopidogrel
– cerebrovascular disease 269
– coronary vascular disease 246f.
– peripheral arterial disease 282
– “resistance” 303
Clopidogrel for High Atherothrombotic Risk, Ischemic Stabilization, Management and Avoidance (CHARISMA) 247f.
Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) 246, 269
Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) 229, 240, 246, 269, 282
Collaborative low-dose aspirin study in pregnancy (CLASP) 227, 293ff.
Colorectal cancer 343ff.
– actual situation 352ff.
– clinical trials 346ff.
– COX-2 expression and aspirin 61f., 120f., 344ff.
– etiology 344f.
– mode of aspirin action 345f.
– NSAIDs 352
– pathophysiology 344ff.
Combination Hemotherapy and Mortality Prevention Study (CHAMP) 248
Coronary vascular diseases 411ff.
– actual situation 250ff.
– acute coronary syndrome (ACS) 238ff.
– aspirin historical use 15f.
– anticoagulants 247ff.
– Clopidogrel 246f.
– coronary artery bypass grafting 244ff.
– coxibs 249f.
– coronary artery bypass graft surgery (CABG) 244ff.
– etiology 228f.
– mode of aspirin action 229ff.
– NSAIDs 249
– percutaneous coronary interventions (PCI) 243f.
– primary prevention 231ff.
Index 373

– secondary prevention 238ff.
Cottbus Reinfarction Trial 240f.
COX
– atherosclerosis 95f.
– gastric mucosa 160f.
– gene expression 14, 61, 359
– historical aspects 13ff.
– inhibition by NSAIDs 54ff., 171, 335ff., 363
– lipoxins 59
– role in asthma 199f.
– transcription factors 69ff.
COX-1
– acetylation by aspirin 56ff.
– active site 55f.
– aspirin-induced asthma 199f.
– 12-HPETE 62
– inhibition by aspirin 54ff.
– interaction with NSAIDs 308
– platelet function 90ff.
COX-2
– acetylation by aspirin 59ff.
– gene expression 61, 120f., 359
– inhibition by aspirin 56ff., 163
– lipoxins 59
– platelet function 90ff.
– tumor promotion 120ff., 345, 350
COX-3 111
Coxibs
– cardiovascular risk 335f.
– interactions with aspirin 108, 170f.
Critical Leg Ischemia Prevention Study (CLIPS) 279, 281
Cyclooxygenases, see COX

Deep vein thrombosis, see Venous thrombosis
Desmopressin 146
Diabetes 183
Dicarboxylic acids 81, 209
Diprydamole 267ff., 280, 282f.
Dipyrrone 308
Disease-modifying Antirheumatic Drugs (DMARDs) 332, 334
Ductus arteriosus 151f.
Dutch TIA Trial 265f.

Endocannabinoids 111
Endothelium
– antiplatelet factors 96f.
– atherosclerosis 95ff.
– dysfunction 278
– inflammation 108f.
– NO-synthase (eNOS) 74f.
– prostaglandin production 95ff.

Energy metabolism 79ff.
European and Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) 268
European Stroke Prevention Study-2 (ESPS-2) 267f.

Fatty acid metabolism 80ff.
Ferritin 74
Fertility 150ff.
Fetal development 150f.
Fever 113ff., 323, 326
Fibrinolysis 98f., 242f., 278

Gastrointestinal tract (GI) 157ff.
– aspirin and GI injury 161ff., 170ff.
– clinical trials 166ff.
– coxibs 170f.
– gastric mucosa 358ff.
– gastrointestinal bleeding 159ff.
– Helicobacter pylori 164ff.
– mode of aspirin action 161ff.
– prostaglandins and GI injury 160f.
Global Registry of Acute Coronary Events (GRACE) 227, 251, 276

Habituation 139
Headache, see Pain
Health Professionals Follow-up Study (HPFS) 347ff.
Hearing disturbances, see Ototoxicity
Heart failure 183f.
Heart Outcomes Prevention Evaluation (HOPE) 310ff.
Helicobacter pylori 164ff.
Heme oxygenase 174f.
Hemorrhage, see Bleeding disorders
Hemorrhagic stroke, see Cerebrovascular diseases
Hemostasis 89ff.
Hepatomecephalopathy, see Reye’s syndrome
Hypertension 183, 235
Hypertension in pregnancy, see Preeclampsia
Hypertension Optimal Treatment study (HOT) 234ff., 260, 264f.
Hyperthermia 137f.
Hyperventilation 79, 134f.

Ibuprofen 56f., 60, 151, 171, 324
Indomethacin 56f., 143f., 151, 171
Inflammation 74, 105ff., 231
Inflammation marker 232
International Stroke Trial (IST) 266
Index

Ischemia, see individual organs
Isoprostanes 94, 309

j
Jamaica Low-Dose Aspirin Study Project (JLASP) 294, 297

k
Kawasaki disease 339ff.
– clinical trials 340
– mode of aspirin action 339
– pathophysiology 339
– Reye’s syndrome 217, 340
Kidney 179ff.
– analgesic nephropathy 179f.
– clinical studies 181f.
– diabetes 183
– mode of aspirin action 180
Kinases 66ff.
Leukotrienes
– asthma 198ff.
– inflammation 106, 108
– ototoxicity 193
Lipoxins, see also Aspirin-triggered Lipoxin 108
Liver 187ff.
– aspirin actions 80ff., 187
– drugs and liver injury 84, 187
– hepatotoxicity of salicylates 84f., 187, 210f.
– Reye’s syndrome 84f.
Lyell syndrome 206

m
Malignancies 118ff., 343ff.
Malondialdehyde 122
Management of Atherothrombosis with Clopidogrel in High-risk Patients with recent Transient Ischemic Attack or Ischemic Stroke (MATCH) 269
Maximal Individual Optimized Therapy for Acute Myocardial Infarction (MITRA) 251
Melbourne Colorectal Cancer Study 346
Metamizol, see Dipyrone
Methylsalicylate 27
Migraine 326ff.
Myocardial infarction, see Coronary vascular diseases
Myocardial Infarction Registry (MIR) 251

n
Neuroprotection 72f., 360
Nitric oxide (NO) 73, 96f., 164
– endothelial NO-synthase (eNOS) 74, 143
– inducible NO-synthase (iNOS) 73f., 106
Nonsteroidal antiinflammatory drugs (NSAIDs)
– Alzheimer’s disease 360ff.
– antiplatelet effects of aspirin 60, 249f., 308
– asthma 199f.
– colorectal carcinoma 346ff.
– COX-1/COX-2-selectivity 55f.
– Ductus arteriosus 151, 292f.
– GI-effects 160f., 170f.
– interactions with aspirin 60f.
– miscarriage 151
– mode of action 60, 108
– osteoarthritis 333, 336
– renal effects 181f.
– Nuclear factor kB (NFkB) 70ff., 123
– Nuclear factor of activated T-cells (NFAT) 70f.
Nurses’ Health Study (NHS) 181, 227, 348ff.

o
Orbital Atherectomy Study for Treatment of Peripheral Vascular Stenosis (OASIS) 248
Organ toxicity 157ff.
Osteoarthritis 171, 333, 336
– acetaminophen 335
– clinical trials 334
Ototoxicity 191ff.
– clinical trials 193f.
– hearing disturbances 191f.
– mode of aspirin action 191f.
– pathophysiology 191
– tinnitus 192
Oxidative phosphorylation 82ff.

p
Pain 110ff., 322ff.
– acetaminophen 324ff.
– cannabinoids 111
– clinical studies 326ff.
– headache 326ff.
– mediators of pain 110ff.
– migraine 326ff.
– mode of aspirin action 111f., 323ff.
– prostaglandins 110f.
– serotonin 112
Paracetamol, see Acetaminophen
Perinatal Antiplatelet Review of International Studies (PARIS) 295, 297ff.
Peripheral Arterial Disease (PAD) 276ff.
– actual situation 283
– clinical trials 278ff.
– etiology 276
– mode of aspirin action 276ff.
– other drug treatment 282f.
– peripheral transluminal angioplasty 281f.
Phenacetin 180
Physicians’ Health Study, see US-Physicians’ Health Study
Platelets 89ff.
– aspirin-insensitive inhibition 309, 315
– bleeding time 143
– cyclooxygenases 56ff., 308f.
– inhibition by aspirin 90ff.
– response variability, see also “resistance” 261ff., 303ff.
– thrombotic risk 229ff., 276ff.
– thromboxane formation 91ff., 306f.
– time-dependent inhibition 91
Preeclampsia 290ff.
– actual situation 298
– clinical trials 293ff.
– etiology 290
– miscarriage 151, 298
– mode of aspirin action 290f.
Pregnancy 150ff.
Pregnancy-induced hypertension, see Preeclampsia
Prevention Regimen For Effectively avoiding Second Strokes (PROFESS) 268ff.
Primary Prevention Project (PPP) 170, 236ff., 264
Prostacyclin, see also Prostaglandins 95ff., 291f.
Prostaglandins
– biosynthesis 55ff.
– general aspects 12f.
– mode of aspirin action 11ff., 55
– pain mediators 110f.
– receptors 122
Prostaglandin synthases, see COX

R
“Resistance” 303ff.
– clinical trials 262, 310ff.
– definition 304
– measurement 304ff.
– mechanisms 303ff.
– role of thromboxane 306f.
Reye’s syndrome 208ff.
– actual situation 217f.
– asthma 217f.
– clinical studies 212ff.
– etiology 209
– laboratory findings 209
– morphological findings 209
– pathophysiology 210
– salicylates 84f., 211ff.
Rheumatoid arthritis 332f.
– clinical studies 250, 334ff.
– mode of aspirin action 332f.
– myocardial infarction 330, 336
– pathophysiology 332
Rotterdam Study 362

S
Salicin 6, 26, 334f.
Salicylate
– antiinflammatory actions 107f.
– antipyretic actions 115
– biotransformations 47f.
– bleeding 98, 142f.
– chemical properties 25ff.
– determination 30f.
– energy metabolism 79ff.
– excretion 49f.
– fatty acid metabolism 80ff.
– gastric mucosal injury 162
– history 19ff.
– inhibition of kinases 67ff.
– inhibition of prostaglandin synthesis 56f.
– natural sources 6, 42f.
– pharmacokinetics 38, 48ff.
– preeclampsia 291f.
– protonophoric properties 83ff.
– thrombotic events 277
– toxicity 132ff.
– transcription factors 61f., 69ff.
– uncoupling of oxidative phosphorylation 82ff.
Salicylic acid, see Salicylate
Serotonin 112
Stroke, see Cerebrovascular diseases
Study of Left Ventricular Dysfunction (SOLVD) 249
Swedish Angina Pectoris Aspirin Trial (SAPAT) 237ff.
Swedish Aspirin Low-Dose Trial (SALT) 266
Sydney Older Persons Study 361

T
Thrombin 89, 144
Thrombosis 90
Thrombosis Primary Prevention Trial (TPT) 170, 236ff., 264
Thrombotic risk 229ff., 244ff., 261ff., 276ff., 287, 290f.
Thromboxane (A2)
– aspirin “resistance” 306f.
– biosynthesis 12f.
– inhibition 91, 97, 229, 261f., 292, 455
– urinary excretion 277, 306f.
Tinnitus, see also Ototoxicity 192
Toxicity, see also individual organs 131ff.
– clinical symptoms 131ff.
– dose-dependency 133ff.
– intoxication in children 135f.
– laboratory findings 135
– treatment 136ff.
Transcription factors
– colorectal carcinoma 123f.
– modulation by salicylates 69ff.

U
United Kingdom Transient Ischemic Attack Aspirin Trial (UK-TIA) 265
Index

(First) United Kingdom Heart and Renal Protection Study (UK-HARP) 183
US-Physicians’ Health Study (US-PHS) 169, 231f., 278, 349f.
US-Public Health Service Study (PHS) 213f.
Urticaria 205

V
Variability in antiplatelet responses, see “Resistance”
Venous thrombosis 287ff.
— actual situation 288
— air travelling 288

W
Warfarin, see Anticoagulants
Warfarin Antiplatelet Vascular Evaluation (WAVE) 270
Widal’s Triad, see Aspirin-induced asthma
Women’s Health Study (WHS) 227, 234f., 263f.